| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| T-Lymphocytes | 25 | 2025 | 1689 | 3.830 |
Why?
|
| Glioblastoma | 13 | 2023 | 330 | 3.610 |
Why?
|
| Immunotherapy, Adoptive | 16 | 2025 | 844 | 2.850 |
Why?
|
| Receptor, ErbB-2 | 13 | 2025 | 509 | 2.560 |
Why?
|
| Receptors, Antigen, T-Cell | 13 | 2020 | 452 | 2.320 |
Why?
|
| Brain Neoplasms | 13 | 2023 | 1217 | 2.200 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 5 | 2018 | 20 | 1.840 |
Why?
|
| Immunotherapy | 11 | 2017 | 727 | 1.840 |
Why?
|
| Sarcoma | 3 | 2025 | 205 | 1.300 |
Why?
|
| Adoptive Transfer | 6 | 2015 | 231 | 1.280 |
Why?
|
| Immunological Synapses | 2 | 2025 | 30 | 1.010 |
Why?
|
| Medulloblastoma | 5 | 2020 | 380 | 0.960 |
Why?
|
| Membrane Microdomains | 1 | 2025 | 58 | 0.880 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2025 | 115 | 0.850 |
Why?
|
| Antigens, Neoplasm | 4 | 2020 | 406 | 0.820 |
Why?
|
| Neoplasms | 6 | 2025 | 2814 | 0.790 |
Why?
|
| Tumor Microenvironment | 4 | 2016 | 617 | 0.710 |
Why?
|
| Antigenic Variation | 2 | 2018 | 37 | 0.700 |
Why?
|
| Tumor Escape | 3 | 2016 | 61 | 0.670 |
Why?
|
| Liver Diseases | 2 | 2019 | 377 | 0.660 |
Why?
|
| Receptor, EphA2 | 2 | 2018 | 28 | 0.660 |
Why?
|
| Muscle Neoplasms | 1 | 2020 | 22 | 0.660 |
Why?
|
| Flow Cytometry | 6 | 2017 | 754 | 0.640 |
Why?
|
| Cancer Vaccines | 3 | 2020 | 184 | 0.620 |
Why?
|
| Blood Specimen Collection | 1 | 2019 | 45 | 0.610 |
Why?
|
| Cerebellar Neoplasms | 3 | 2020 | 314 | 0.610 |
Why?
|
| Mice, SCID | 9 | 2023 | 560 | 0.590 |
Why?
|
| Rhabdomyosarcoma | 1 | 2020 | 208 | 0.540 |
Why?
|
| Leukocytes, Mononuclear | 4 | 2022 | 333 | 0.530 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2017 | 143 | 0.520 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2017 | 507 | 0.510 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2023 | 1154 | 0.510 |
Why?
|
| Vidarabine | 2 | 2024 | 85 | 0.500 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 1219 | 0.500 |
Why?
|
| Transplantation Conditioning | 3 | 2018 | 303 | 0.500 |
Why?
|
| Xenograft Model Antitumor Assays | 10 | 2025 | 926 | 0.480 |
Why?
|
| Cell Line, Tumor | 11 | 2025 | 3436 | 0.480 |
Why?
|
| Hematologic Neoplasms | 4 | 2025 | 293 | 0.480 |
Why?
|
| Antibodies, Monoclonal | 2 | 2014 | 988 | 0.480 |
Why?
|
| Viral Matrix Proteins | 2 | 2015 | 107 | 0.480 |
Why?
|
| Microspheres | 1 | 2015 | 69 | 0.470 |
Why?
|
| Immediate-Early Proteins | 1 | 2015 | 57 | 0.460 |
Why?
|
| Humans | 54 | 2025 | 125613 | 0.460 |
Why?
|
| Immunophenotyping | 1 | 2015 | 330 | 0.440 |
Why?
|
| Phosphoproteins | 1 | 2015 | 418 | 0.400 |
Why?
|
| Lymphoma | 2 | 2024 | 313 | 0.370 |
Why?
|
| Membrane Proteins | 1 | 2019 | 1543 | 0.360 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2014 | 192 | 0.360 |
Why?
|
| Mice | 20 | 2025 | 17528 | 0.350 |
Why?
|
| Neoplastic Stem Cells | 2 | 2013 | 328 | 0.350 |
Why?
|
| Chemotaxis | 1 | 2011 | 59 | 0.350 |
Why?
|
| Osteosarcoma | 2 | 2015 | 258 | 0.340 |
Why?
|
| Animals | 24 | 2025 | 33094 | 0.330 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 425 | 0.330 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2017 | 724 | 0.330 |
Why?
|
| Antigens, Viral | 1 | 2012 | 391 | 0.330 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2010 | 55 | 0.320 |
Why?
|
| Cytomegalovirus | 3 | 2017 | 258 | 0.310 |
Why?
|
| Tumor Cells, Cultured | 5 | 2020 | 991 | 0.300 |
Why?
|
| CD28 Antigens | 2 | 2025 | 74 | 0.300 |
Why?
|
| Yellow Fever Vaccine | 1 | 2009 | 42 | 0.300 |
Why?
|
| Antibodies, Neoplasm | 1 | 2008 | 56 | 0.290 |
Why?
|
| Yellow Fever | 1 | 2009 | 78 | 0.290 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2025 | 255 | 0.280 |
Why?
|
| Male | 21 | 2025 | 61966 | 0.280 |
Why?
|
| Endothelial Cells | 1 | 2011 | 505 | 0.270 |
Why?
|
| beta-Thalassemia | 1 | 2007 | 26 | 0.270 |
Why?
|
| Treatment Outcome | 7 | 2024 | 12334 | 0.270 |
Why?
|
| Lymphocyte Depletion | 2 | 2024 | 119 | 0.260 |
Why?
|
| Child | 15 | 2025 | 25015 | 0.260 |
Why?
|
| Cell Proliferation | 5 | 2018 | 2383 | 0.250 |
Why?
|
| Oncogenic Viruses | 1 | 2006 | 17 | 0.250 |
Why?
|
| Antineoplastic Agents | 3 | 2016 | 1738 | 0.250 |
Why?
|
| Signal Transduction | 2 | 2025 | 4446 | 0.250 |
Why?
|
| Cell Transformation, Viral | 1 | 2006 | 95 | 0.250 |
Why?
|
| Endoglin | 1 | 2025 | 30 | 0.240 |
Why?
|
| Genome, Viral | 1 | 2006 | 153 | 0.240 |
Why?
|
| Tumor Virus Infections | 1 | 2006 | 131 | 0.240 |
Why?
|
| Pneumococcal Infections | 1 | 2007 | 277 | 0.230 |
Why?
|
| Cyclophosphamide | 2 | 2024 | 417 | 0.230 |
Why?
|
| Streptococcus pneumoniae | 1 | 2007 | 379 | 0.230 |
Why?
|
| Vaccines | 1 | 2010 | 379 | 0.230 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2025 | 26 | 0.230 |
Why?
|
| Lymphocyte Activation | 4 | 2025 | 669 | 0.220 |
Why?
|
| Graft Rejection | 1 | 2008 | 554 | 0.220 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2024 | 429 | 0.210 |
Why?
|
| Alemtuzumab | 2 | 2018 | 86 | 0.210 |
Why?
|
| Adult | 9 | 2024 | 30189 | 0.210 |
Why?
|
| Anemia, Sickle Cell | 1 | 2007 | 324 | 0.200 |
Why?
|
| Mice, Inbred NOD | 3 | 2023 | 285 | 0.200 |
Why?
|
| Female | 16 | 2025 | 67790 | 0.200 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 51 | 0.190 |
Why?
|
| Child, Preschool | 11 | 2025 | 14316 | 0.190 |
Why?
|
| Oncolytic Viruses | 1 | 2023 | 75 | 0.190 |
Why?
|
| Adolescent | 10 | 2025 | 19904 | 0.190 |
Why?
|
| Oncolytic Virotherapy | 1 | 2023 | 89 | 0.190 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2024 | 147 | 0.190 |
Why?
|
| Leukemia | 1 | 2024 | 354 | 0.170 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 317 | 0.170 |
Why?
|
| Antigens, CD19 | 2 | 2020 | 165 | 0.170 |
Why?
|
| Glioma | 2 | 2017 | 475 | 0.170 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2020 | 61 | 0.160 |
Why?
|
| Leukemia, B-Cell | 1 | 2020 | 23 | 0.160 |
Why?
|
| Middle Aged | 5 | 2024 | 27263 | 0.160 |
Why?
|
| Prospective Studies | 3 | 2024 | 6162 | 0.160 |
Why?
|
| Cerebrospinal Fluid | 1 | 2020 | 91 | 0.160 |
Why?
|
| Immunologic Memory | 1 | 2021 | 191 | 0.160 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 261 | 0.160 |
Why?
|
| Freezing | 1 | 2019 | 24 | 0.160 |
Why?
|
| Remission Induction | 1 | 2020 | 298 | 0.160 |
Why?
|
| Biopsy | 2 | 2020 | 1218 | 0.160 |
Why?
|
| Transduction, Genetic | 4 | 2020 | 281 | 0.150 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2022 | 213 | 0.150 |
Why?
|
| Transgenes | 2 | 2020 | 330 | 0.150 |
Why?
|
| Protein Stability | 1 | 2019 | 159 | 0.150 |
Why?
|
| Follow-Up Studies | 6 | 2025 | 5079 | 0.150 |
Why?
|
| Ependymoma | 1 | 2020 | 138 | 0.150 |
Why?
|
| Bone Marrow | 1 | 2020 | 304 | 0.150 |
Why?
|
| Aged | 4 | 2024 | 19970 | 0.140 |
Why?
|
| Infant | 7 | 2025 | 12758 | 0.140 |
Why?
|
| Osteopontin | 1 | 2018 | 51 | 0.140 |
Why?
|
| Wiskott-Aldrich Syndrome | 1 | 2017 | 23 | 0.140 |
Why?
|
| Neoplasms, Experimental | 2 | 2010 | 204 | 0.140 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2018 | 71 | 0.140 |
Why?
|
| Severe Combined Immunodeficiency | 2 | 2008 | 104 | 0.130 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 678 | 0.130 |
Why?
|
| Molecular Imaging | 1 | 2017 | 61 | 0.130 |
Why?
|
| Herpesvirus 4, Human | 2 | 2017 | 615 | 0.130 |
Why?
|
| Protein Binding | 2 | 2020 | 1663 | 0.120 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2018 | 198 | 0.120 |
Why?
|
| Adenoviridae | 2 | 2017 | 576 | 0.120 |
Why?
|
| Transplantation, Homologous | 1 | 2018 | 637 | 0.120 |
Why?
|
| Interleukin-13 | 1 | 2016 | 94 | 0.120 |
Why?
|
| HEK293 Cells | 2 | 2020 | 762 | 0.120 |
Why?
|
| Polystyrenes | 1 | 2015 | 8 | 0.120 |
Why?
|
| Survival Rate | 4 | 2017 | 2041 | 0.120 |
Why?
|
| Autoimmune Diseases | 1 | 2018 | 264 | 0.120 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 358 | 0.120 |
Why?
|
| Protein Multimerization | 1 | 2016 | 144 | 0.120 |
Why?
|
| Receptors, Cell Surface | 1 | 2017 | 423 | 0.120 |
Why?
|
| Genetic Engineering | 1 | 2016 | 159 | 0.120 |
Why?
|
| Color | 1 | 2015 | 33 | 0.120 |
Why?
|
| Neuroectodermal Tumors | 1 | 2015 | 12 | 0.120 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2018 | 222 | 0.110 |
Why?
|
| Neurodegenerative Diseases | 1 | 2018 | 270 | 0.110 |
Why?
|
| Maximum Tolerated Dose | 1 | 2015 | 172 | 0.110 |
Why?
|
| In Situ Hybridization | 2 | 2013 | 455 | 0.110 |
Why?
|
| Apoptosis | 2 | 2018 | 1795 | 0.110 |
Why?
|
| Recurrence | 2 | 2015 | 1403 | 0.110 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 266 | 0.110 |
Why?
|
| Separase | 1 | 2014 | 28 | 0.110 |
Why?
|
| Leukocytes | 1 | 2015 | 203 | 0.110 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 964 | 0.110 |
Why?
|
| Fluorescent Dyes | 1 | 2015 | 249 | 0.110 |
Why?
|
| Antibodies | 1 | 2015 | 350 | 0.110 |
Why?
|
| Astrocytes | 1 | 2017 | 259 | 0.110 |
Why?
|
| Sarcoma, Ewing | 1 | 2015 | 110 | 0.110 |
Why?
|
| Cells, Cultured | 2 | 2010 | 2896 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2017 | 657 | 0.100 |
Why?
|
| Antigens, CD1d | 1 | 2013 | 20 | 0.100 |
Why?
|
| NFI Transcription Factors | 1 | 2013 | 50 | 0.100 |
Why?
|
| Synapses | 1 | 2017 | 430 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 780 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2015 | 284 | 0.100 |
Why?
|
| Retroviridae | 2 | 2012 | 180 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 1023 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2025 | 2002 | 0.090 |
Why?
|
| Natural Killer T-Cells | 1 | 2013 | 84 | 0.090 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 902 | 0.090 |
Why?
|
| Cell Nucleus | 1 | 2014 | 557 | 0.090 |
Why?
|
| Biomarkers, Tumor | 2 | 2017 | 1560 | 0.090 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2024 | 199 | 0.090 |
Why?
|
| Up-Regulation | 1 | 2014 | 827 | 0.090 |
Why?
|
| Receptors, Antigen | 1 | 2011 | 33 | 0.090 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2011 | 15 | 0.090 |
Why?
|
| Cell Separation | 1 | 2012 | 218 | 0.090 |
Why?
|
| Chemokine CCL5 | 1 | 2011 | 52 | 0.090 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 786 | 0.090 |
Why?
|
| Retrospective Studies | 6 | 2025 | 16725 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2015 | 764 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 962 | 0.080 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2011 | 127 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2013 | 601 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 1228 | 0.080 |
Why?
|
| Biological Assay | 1 | 2010 | 105 | 0.080 |
Why?
|
| Cytomegalovirus Infections | 1 | 2012 | 220 | 0.080 |
Why?
|
| Mice, Inbred ICR | 1 | 2010 | 151 | 0.080 |
Why?
|
| Young Adult | 3 | 2024 | 9556 | 0.080 |
Why?
|
| Tumor Burden | 1 | 2010 | 228 | 0.080 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 1343 | 0.070 |
Why?
|
| Transplantation Chimera | 1 | 2008 | 45 | 0.070 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 269 | 0.070 |
Why?
|
| Models, Biological | 1 | 2013 | 1369 | 0.070 |
Why?
|
| Th1 Cells | 1 | 2009 | 148 | 0.070 |
Why?
|
| Lymphocyte Transfusion | 1 | 2008 | 57 | 0.070 |
Why?
|
| Immunohistochemistry | 2 | 2013 | 1599 | 0.070 |
Why?
|
| Th2 Cells | 1 | 2009 | 185 | 0.070 |
Why?
|
| Cytokines | 2 | 2020 | 1313 | 0.070 |
Why?
|
| Genetic Therapy | 1 | 2012 | 679 | 0.070 |
Why?
|
| Living Donors | 1 | 2008 | 115 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 1476 | 0.070 |
Why?
|
| Brain | 3 | 2018 | 3016 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 1973 | 0.070 |
Why?
|
| Metabolic Diseases | 1 | 2008 | 129 | 0.070 |
Why?
|
| Fatal Outcome | 1 | 2007 | 354 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2013 | 864 | 0.060 |
Why?
|
| Gene Expression | 2 | 2022 | 1486 | 0.060 |
Why?
|
| Immunity, Innate | 1 | 2009 | 389 | 0.060 |
Why?
|
| Antigen-Presenting Cells | 1 | 2007 | 132 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2015 | 4878 | 0.060 |
Why?
|
| Prognosis | 3 | 2025 | 4668 | 0.060 |
Why?
|
| Cell Communication | 1 | 2007 | 181 | 0.060 |
Why?
|
| Monocytes | 1 | 2007 | 329 | 0.060 |
Why?
|
| Pediatrics | 1 | 2014 | 1205 | 0.060 |
Why?
|
| Acute Disease | 1 | 2007 | 1038 | 0.060 |
Why?
|
| Immunocompromised Host | 1 | 2006 | 297 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2008 | 541 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2025 | 131 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2025 | 123 | 0.050 |
Why?
|
| Coculture Techniques | 2 | 2017 | 228 | 0.050 |
Why?
|
| Graft vs Host Disease | 1 | 2008 | 622 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 3557 | 0.050 |
Why?
|
| Busulfan | 1 | 2023 | 46 | 0.050 |
Why?
|
| Mice, Transgenic | 2 | 2020 | 2316 | 0.050 |
Why?
|
| Neutropenia | 1 | 2024 | 198 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2022 | 2547 | 0.050 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 223 | 0.050 |
Why?
|
| Egypt | 1 | 2022 | 26 | 0.050 |
Why?
|
| Biological Products | 1 | 2024 | 130 | 0.050 |
Why?
|
| Ghrelin | 1 | 2022 | 57 | 0.050 |
Why?
|
| TRPV Cation Channels | 1 | 2022 | 45 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2023 | 4419 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2006 | 776 | 0.040 |
Why?
|
| Injections, Intraventricular | 1 | 2020 | 55 | 0.040 |
Why?
|
| Biomarkers | 2 | 2020 | 3130 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2020 | 203 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 563 | 0.040 |
Why?
|
| Chimerism | 1 | 2018 | 29 | 0.040 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2018 | 29 | 0.040 |
Why?
|
| Pancytopenia | 1 | 2018 | 40 | 0.040 |
Why?
|
| Unrelated Donors | 1 | 2018 | 71 | 0.030 |
Why?
|
| Oxidoreductases Acting on CH-NH Group Donors | 1 | 2017 | 25 | 0.030 |
Why?
|
| Antigens | 1 | 2017 | 145 | 0.030 |
Why?
|
| Biotechnology | 1 | 2017 | 57 | 0.030 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2017 | 40 | 0.030 |
Why?
|
| Allografts | 1 | 2017 | 183 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2018 | 263 | 0.030 |
Why?
|
| MAP Kinase Signaling System | 1 | 2018 | 295 | 0.030 |
Why?
|
| Microscopy | 1 | 2017 | 127 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2014 | 1918 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 264 | 0.030 |
Why?
|
| Genotype | 1 | 2022 | 2597 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2018 | 8362 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2017 | 331 | 0.030 |
Why?
|
| Interleukin-13 Receptor alpha1 Subunit | 1 | 2014 | 6 | 0.030 |
Why?
|
| Immunotoxins | 1 | 2014 | 21 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2018 | 498 | 0.030 |
Why?
|
| Chick Embryo | 1 | 2013 | 113 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 135 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2013 | 229 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2014 | 395 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 1815 | 0.020 |
Why?
|
| K562 Cells | 1 | 2012 | 93 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2012 | 231 | 0.020 |
Why?
|
| Seizures | 1 | 2017 | 850 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2014 | 581 | 0.020 |
Why?
|
| Neuroglia | 1 | 2013 | 206 | 0.020 |
Why?
|
| Antigen Presentation | 1 | 2011 | 115 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 1289 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 1235 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2017 | 3295 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 3182 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2012 | 513 | 0.020 |
Why?
|
| Luciferases | 1 | 2010 | 126 | 0.020 |
Why?
|
| Transcriptome | 1 | 2017 | 1063 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2012 | 890 | 0.020 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2011 | 272 | 0.020 |
Why?
|
| Cell Survival | 1 | 2010 | 824 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 994 | 0.020 |
Why?
|
| Rats | 1 | 2013 | 3388 | 0.020 |
Why?
|
| B7-1 Antigen | 1 | 2007 | 11 | 0.020 |
Why?
|
| Neurons | 1 | 2017 | 1908 | 0.020 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2007 | 53 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 2007 | 156 | 0.020 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2007 | 132 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2007 | 412 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2007 | 406 | 0.010 |
Why?
|
| Dendritic Cells | 1 | 2007 | 425 | 0.010 |
Why?
|
| Risk Factors | 1 | 2017 | 10346 | 0.010 |
Why?
|